Document Preview Unavailable
A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants
Ana Liza Andresan Sun; Gillies, John David; Shen, Yang; Deng, Huajun; Xue, Fenchao; et al. Clinical and Translational Science Vol. 17, Iss. 7, (Jul 2024).You might have access to this document
-
Try and log in through your institution to see if they have access to the full text.
Log in through your library